country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

209 Results for "

Competitive Inhibition

" in MedChemExpress (MCE) Product Catalog:

Products (209)

Sort by :

Categories

By Targets

Products

657

Adezmapimod

657 Publications Verification

Cat. No.: HY-10256

CAS No.: 152121-47-6

Purity: 99.92%

Synonyms: SB 203580; RWJ 64809

Target:

Organoid p38 MAPK Autophagy Mitophagy HSP

Research Areas:

Inflammation/Immunology Cancer

Adezmapimod (SB 203580) is a selective and ATP-competitive p38 MAPK inhibitor with IC₅₀s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod inhibits LCK, GSK3β and PKBα with IC₅₀s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod can inhibit p38 MAPK and lead to the inhibition of downstream HSP27 phosphorylation. Adezmapimod does not disrupt JNK activity and is an autophagy and mitophagy activator .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

Crizotinib

92 Cited Publications

Cat. No.: HY-50878

CAS No.: 877399-52-5

Synonyms: PF-02341066

Target:

Ligands for Target Protein for PROTAC Anaplastic lymphoma kinase (ALK) c-Met/HGFR ROS Kinase

Research Areas:

Cancer

Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

Crizotinib hydrochloride

92 Cited Publications

Cat. No.: HY-50878A

CAS No.: 1415560-69-8

Synonyms: PF-02341066 hydrochloride

Target:

Anaplastic lymphoma kinase (ALK) c-Met/HGFR ROS Kinase Autophagy

Research Areas:

Cancer

Crizotinib hydrochloride (PF-02341066 hydrochloride) is an orally bioavailable, selective, and ATP-competitive dual ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib hydrochloride (PF-02341066 hydrochloride) inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. It is also a ROS proto-oncogene 1 (ROS1) inhibitor. Crizotinib hydrochloride (PF-02341066 hydrochloride) has effective tumor growth inhibition .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

Ipatasertib

71 Cited Publications

Cat. No.: HY-15186

CAS No.: 1001264-89-6

Purity: 99.79%

Synonyms: GDC-0068; RG7440

Target:

Organoid Akt Apoptosis

Research Areas:

Cancer

Ipatasertib (GDC-0068) is an orally active, highly selective and ATP-competitive pan-Akt inhibitor with IC₅₀ values of 5, 18, 8 nM for Akt1/2/3, respectively. Ipatasertib synchronously activates FoxO3a and NF-κB through inhibition of Akt leading to p53-independent activation of PUMA. Ipatasertib also induces apoptosis in cancer cells and inhibits tumor growth in xenograft mouse models .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

SAR405

42 Cited Publications

Cat. No.: HY-12481

CAS No.: 1523406-39-4

Purity: 99.74%

Target:

PI3K Autophagy

Research Areas:

Cancer

SAR405 is a first-in-class, selective, and ATP-competitive PI3K class III (PIK3C3) isoform Vps34 inhibitor (IC₅₀=1.2 nM; K_d=1.5 nM). SAR405 inhibits autophagy induced either by starvation or by mTOR inhibition. Anticancer activity .

Compare